With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.690261-64-4,2-(Piperidin-4-yl)pyrimidine hydrochloride,as a common compound, the synthetic route is as follows.
690261-64-4, Ketone Intermediate 1 (100 mg, 0.253 mmol) was combined with 4- (5-pyrimidyl)-piperidine hydrochloride (prepared as described for Intermediate 5,90 mg, 0.38 mmol), triethylamine (105 P, L, 0.759 mmol), sodium triacetoxyborohydride (212 mg, 1.00 mmol) and 4 A molecular sieves (powder, 100 mg) in DCM (10 mL). The reaction mixture was stirred at rt for 2 days, then was filtered through a celite plug. The filtrate was concentrated and purified by preparative TLC (silica, 5% of 1: 9 NHMOH/METHANOL in DCM, then a second plate with 10% methanol/DCM) to afford two bands corresponding to the cis (top spot) and trans isomers (bottom spot). Both the cis and trans isomers were converted to HC1 salts by dissolving the free bases in-1 mL of DCM, adding excess 1 N HCL in ether, and concentrating. Top spot-ESI-MS calculated for C27H32F6N40: 542; Found: 543 (M+H). Bottom spot-ESI-MS calculated for C27H32F6N40: 542; Found: 543 (M+H). Single cis-enantiomers were obtained via chiral HPLC, using Diacel’s Chiralcel AD semipreparative column, eluting with 10% ethanol/hexane (using the free base). The observed retention times of the respective diastereoisomers were 25 and 38 minutes, respectively.
The synthetic route of 690261-64-4 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; MERCK & CO., INC.; WO2004/41777; (2004); A2;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem